CanariaBioM Submits Semiannual Report with 'Appropriate Opinion'
[Asia Economy Reporter Jang Hyowon] Canaria Bio's parent company, Canaria Bio M (K-OTC), announced on the 30th that it completed the submission of the semi-annual report with an 'unqualified opinion' on the 29th.
This year marks the first year that the company’s semi-annual review was conducted by an external auditor on the consolidated financial statements, and the submission deadline for the semi-annual report was extended to August 29, 2022, to prepare the related materials. The biotech company developing immuno-oncology drugs, Canaria Bio, is the consolidation target.
As a result, the delayed submission of the semi-annual report drew heightened concern from shareholders and the market. However, contrary to concerns, Canaria Bio M received the semi-annual report with an 'unqualified opinion' from the external auditor on the afternoon of the same day and completed the submission.
Nahanik, CEO of Canaria Bio M, stated, “Our company received unqualified opinions for all consolidated entities in the semi-annual review, which alleviates shareholders’ concerns. We will do our best to collaborate and continuously strive for the success of the bio business with Canaria Bio.”
A representative of Canaria Bio M added, “Over the past month, the stock price plummeted due to baseless fake news such as ‘disclaimer of opinion,’ ‘K-OTC registration cancellation,’ ‘breach of trust,’ and ‘embezzlement.’ We will strongly respond legally to any future dissemination of fake news that damages our shareholder value.”
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Meanwhile, the subsidiary Canaria Bio is currently recruiting patients for the global Phase 3 clinical trial of ‘Oregovomab’ across 16 countries and approximately 152 sites. Recently, it surpassed 60% of the recruitment target of 602 patients and is accelerating patient recruitment by adding clinical sites in India. Accordingly, the interim results are expected to be announced in the third quarter of next year as originally planned.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
